קורונה בישראל: 1,348,800 מקרים מאומתים (432+ מחצות) | 5,798 פעילים | 90 במצב קשה (55 מונשמים) | 8,210 נפטרים | 675 מאומתים אתמול  

The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of chloroquine or hydroxychloroquine and/or azithromycin for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AIIa).

Recommendation 1. Among hospitalized patients with COVID-19, the IDSA guideline panel recommends against hydroxychloroquine*. (Strong recommendation, Moderate certainty of evidence)

Remark: Chloroquine is considered to be class equivalent to hydroxychloroquine.
Recommendation 2. Among hospitalized patients with COVID-19, the IDSA guideline panel recommends against hydroxychloroquine* plus azithromycin. (Strong recommendation, Low certainty of evidence)

Remark: Chloroquine is considered to be class equivalent to hydroxychloroquine.

Recommendation 3: In persons exposed to COVID-19, the IDSA guideline panel recommends against hydroxychloroquine. (Strong recommendation, Low certainty of evidence)

Recommendation 16: In persons exposed to COVID-19 who are at high risk of progression to severe COVID-19, the IDSA guideline panel suggests post-exposure casirivimab/imdevimab rather than no casirivimab/imdevimab. (Conditional recommendation, low certainty of evidence)

Recommendation 17: Among ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab rather than no neutralizing antibody treatment. (Conditional recommendation, Moderate certainty of evidence)

The COVID-19 Treatment Guidelines Panel (the Panel) recommends using one of the following anti-SARS-CoV-2 mAb products (listed alphabetically and not in order of preference) to treat nonhospitalized patients with mild to moderate COVID-19 who are at high risk of clinical progression